TY - JOUR T1 - COVID-19: Effectiveness of Non-Pharmaceutical Interventions in the United States before Phased Removal of Social Distancing Protections Varies by Region JF - medRxiv DO - 10.1101/2020.08.18.20177600 SP - 2020.08.18.20177600 AU - William K. Pan AU - Stefanos Tyrovolas AU - Giné-Vázquez Iago AU - Rishav Raj Dasgupta AU - Fernández Daniel AU - Ben Zaitchik AU - Paul M. Lantos AU - Christopher W. Woods Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/20/2020.08.18.20177600.abstract N2 - Although coronavirus disease 2019 (COVID-19) emerged in January 2020, there is no quantified effect size for non-pharmaceutical interventions (NPI) to control the outbreak in the continental US. Objective. To quantify national and sub-national effect sizes of NPIs in the US. Design. This is an observational study for which we obtained daily county level COVID-19 cases and deaths from January 22, 2020 through the phased removal of social distancing protections. A stepped-wedge cluster-randomized trial (SW-CRT) analytical approach is used, leveraging the phased implementation of policies. Data include 3142 counties from all 50 US states and the District of Columbia. Exposures. County-level NPIs were obtained from online county and state policy databases, then classified into four intervention levels: Level 1 (low) – declaration of a State of Emergency; Level 2 (moderate) – school closures, restricting nursing home access, or closing restaurants and bars; Level 3 (high) – non-essential business closures, suspending non-violent arrests, suspending elective medical procedures, suspending evictions, or restricting mass gatherings of at least 10 people; and Level 4 (aggressive) – sheltering in place / stay-at-home, public mask requirements, or travel restrictions. Additional county-level data were obtained to record racial (Black, Hispanic), economic (educational level, poverty), demographic (rural/urban) and climate factors (temperature, specific humidity, solar radiation). Main Outcomes. The primary outcomes are rates of COVID-19 cases, deaths and case doubling times. NPI effects are measured separately for nine US Census Region (Pacific, Mountain, West North Central, East North Central, West South Central, East South Central, South Atlantic, Middle Atlantic, New England). Results. Aggressive NPIs (level 4) significantly reduced COVID-19 case and death rates in all US Census Regions, with effect sizes ranging from 4.1% to 25.7% and 5.5% to 25.5%, respectively, for each day they were active. No other intervention level achieved significance across all US Regions. Intervention levels 3 and 4 both increased COVID-19 doubling times, with effects peaking at 25 and 40 days after initiation of each policy, respectively. The effectiveness of level 3 NPIs varied, reducing case rates in all regions except North Central states, but associated with significantly higher death rates in all regions except Pacific states. Intervention levels 1 and 2 did not indicate any effect on COVID-19 propagation and, in some regions, these interventions were associated with increased COVID-19 cases and deaths. Heterogeneity of NPI effects are associated with racial composition, poverty, urban-rural environment, and climate factors. Conclusion. Aggressive NPIs are effective tools to reduce COVID-19 propagation and mortality. Reducing social and environmental disparities may improve NPI effects in regions where less strict policies are in place.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was conducted with support from NASA (NNX15AP74G to W.Pan)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data used in this study are from publicly available data sources.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available on public databases. https://coronavirus.jhu.edu/ https://data.census.gov/mdat/#/ https://www.nga.org/coronavirus/#resElections https://www.multistate.us https://www.ers.usda.gov/data-products/rural-urban-continuum-codes/ ER -